Bryan Johnson, the prominent anti-aging influencer and tech entrepreneur, has been diagnosed with autoimmune gastritis, a chronic illness in which his immune system attacks the lining of his stomach. He revealed the diagnosis through a detailed post on the social platform X, where he outlined bad news number one as having an autoimmune disease with his stomach eating itself. He added as bad news number two that two to five percent of people have this too and likely more because it hides. The good news he highlighted is that he is going to try and solve it and will share all the details with the public.
In the same post, Johnson reflected on his earlier life, noting that as a kid he ate sugar cereal, drank sugary soda, and gobbled down fast food. He had a few healthy years in his early twenties, but then became a young father of three and began building a business. Juggling that stress and grind, he let his health slip and gained forty pounds. Within a few years he had fallen into a deep chronic depression, and somewhere in that timeline his body began developing an autoimmune process affecting his thyroid and then his stomach lining.
The condition, which Johnson identified as autoimmune gastritis (AIG), was confirmed through medical testing in May after years of unexplained low iron stores. He had managed hypothyroidism, an autoimmune thyroid issue diagnosed at age twenty-one, with hormone supplements. Recent evaluations included blood tests showing elevated antiparietal cell antibodies at levels roughly five times the normal limit, along with a bidirectional endoscopy and five stomach biopsies that revealed early atrophy in the acid-producing cells. A colonoscopy came back clean, ruling out other concerns, and he received a one thousand milligram iron infusion to address the deficiency.
Johnson, now forty-eight years old and known for his Blueprint protocol focused on extreme health optimization, outlined plans to go beyond standard care. He intends to sequence one million of his immune cells to identify the specific ones attacking his stomach lining. His strategy includes advanced characterization of the disease and a series of experimental interventions ranging from supportive supplements to targeting immune pathways and potentially frontier therapies such as engineered cell treatments. He will continue monitoring key biomarkers, including gastrin levels, and share updates on the process.
Autoimmune gastritis often develops silently, and clinical descriptions of atrophic gastritis note it can lead to irreversible damage, including nutritional deficiencies, anemia, and increased long-term cancer risk, if not addressed early. In Johnson’s case, the connection to his prior thyroid autoimmunity fits patterns observed in related conditions. His decision to pursue resolution through data-driven and innovative methods rather than acceptance of management only adds significant context to discussions around personal health protocols. The transparency in his announcement echoes the high-profile disclosures seen in Celine Dion’s Stiff Person Syndrome battle, showing how public figures with chronic autoimmune disease increasingly share diagnostic detail.
This announcement underscores that even those who invest heavily in continuous health tracking and lifestyle adjustments can face unexpected autoimmune developments rooted in earlier life circumstances and biological factors. By committing to full disclosure of his diagnostic journey and treatment explorations, Johnson contributes to greater public awareness about conditions that hide and the potential for proactive responses. The case also illustrates the value of thorough medical investigations when subtle markers like persistent low iron levels appear without full-blown anemia. His approach may encourage others to seek comprehensive evaluations and explore beyond conventional boundaries in managing similar health issues.
